

Massimo Cristofanilli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4404115/publications.pdf>

Version: 2024-02-01

235
papers

23,429
citations

19608

61
h-index

8138

148
g-index

245
all docs

245
docs citations

245
times ranked

20840
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 781-791.	13.9	4,124
2	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	5.1	1,344
3	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	13.9	1,239
4	Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System. <i>Clinical Cancer Research</i> , 2007, 13, 920-928.	3.2	1,204
5	Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1420-1430.	0.8	1,012
6	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. <i>Clinical Cancer Research</i> , 2006, 12, 4218-4224.	3.2	937
7	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	13.9	805
8	Circulating Tumor Cells versus Imaging Predicting Overall Survival in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6403-6409.	3.2	728
9	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968.	0.8	573
10	Emergence of Constitutively Active Estrogen Receptor Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	3.2	529
11	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	7.7	397
12	Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2005, 23, 41-48.	0.8	352
13	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. <i>Nature Communications</i> , 2018, 9, 896.	5.8	305
14	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 351-375.	157.7	298
15	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2695-2704.	0.8	279
16	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1169-1178.	0.8	266
17	Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. <i>Cancer Discovery</i> , 2019, 9, 96-113.	7.7	256
18	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	5.8	252

#	ARTICLE	IF	CITATIONS
19	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
20	Circulating giant macrophages as a potential biomarker of solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3514-3519.	3.3	229
21	Molecular mechanisms of metastasis in breast cancer—clinical applications. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 693-701.	12.5	208
22	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
23	Thyroid hormone and breast carcinoma. <i>Cancer</i> , 2005, 103, 1122-1128.	2.0	199
24	Inflammatory breast cancer (IBC) and patterns of recurrence. <i>Cancer</i> , 2007, 110, 1436-1444.	2.0	194
25	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	1.9	183
26	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018, 78, 845-852.	0.4	169
27	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 9-14.	0.8	163
28	Angiogenesis modulation in cancer research: novel clinical approaches. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 415-426.	21.5	158
29	Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 83-94.	1.1	156
30	Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1904-1914.	3.2	154
31	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 806-815.	5.1	154
32	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. <i>Cancer Treatment Reviews</i> , 2017, 53, 111-119.	3.4	134
33	Molecular characterization and targeted therapeutic approaches in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 60.	2.2	132
34	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	5.1	131
35	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696.	3.2	130
36	Update on the Management of Inflammatory Breast Cancer. <i>Oncologist</i> , 2003, 8, 141-148.	1.9	126

#	ARTICLE	IF	CITATIONS
37	Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 563-571.	1.1	124
38	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0132710.	1.1	121
39	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 560-568.	3.2	120
40	Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1412-1420.	1.9	114
41	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , 2017, 22, 1028-1038.	1.9	108
42	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2017, 8, 8910-8920.	0.8	108
43	Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e180163.	3.4	105
44	Paclitaxel Improves the Prognosis in Estrogen Receptorâ€”Negative Inflammatory Breast Cancer: The M. D. Anderson Cancer Center Experience. <i>Clinical Breast Cancer</i> , 2004, 4, 415-419.	1.1	100
45	Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 371-381.	1.1	100
46	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. <i>Oncotarget</i> , 2016, 7, 65364-65373.	0.8	99
47	ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. <i>Nature Communications</i> , 2021, 12, 4867.	5.8	97
48	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	2.2	94
49	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	3.4	88
50	Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome. <i>Clinical Breast Cancer</i> , 2015, 15, 1-7.	1.1	85
51	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. <i>Journal of Cancer</i> , 2018, 9, 1437-1447.	1.2	84
52	CTC enumeration and characterization: moving toward personalized medicine. <i>Annals of Translational Medicine</i> , 2014, 2, 108.	0.7	83
53	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <i>PLoS ONE</i> , 2016, 11, e0147400.	1.1	82
54	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2012, 17, 96-104.	1.0	80

#	ARTICLE	IF	CITATIONS
55	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978.	2.0	79
56	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 155-162.	1.1	72
57	Inflammatory breast cancer (IBC): clues for targeted therapies. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 23-33.	1.1	71
58	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 785-795.	1.1	68
59	Detection of Activating Estrogen Receptor Gene (<i>ESR1</i>) Mutations in Single Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 6086-6093.	3.2	68
60	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. <i>Clinical Breast Cancer</i> , 2007, 7, 471-9.	1.1	67
61	International liquid biopsy standardization alliance white paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103112.	2.0	66
62	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2 ⁻ metastatic breast cancer in US real-world clinical practice. <i>Breast Cancer Research</i> , 2021, 23, 37.	2.2	65
63	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	3.2	65
64	Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1665.	1.8	63
65	Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1037-1042.	1.1	61
66	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 309-317.	3.0	60
67	Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. <i>Cancer</i> , 2006, 106, 1000-1006.	2.0	59
68	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	3.0	59
69	Defining the Clinical Diagnosis of Inflammatory Breast Cancer. <i>Seminars in Oncology</i> , 2008, 35, 7-10.	0.8	56
70	GSK-3 inhibition overcomes chemoresistance in human breast cancer. <i>Cancer Letters</i> , 2016, 380, 384-392.	3.2	55
71	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	3.0	55
72	Primary Inflammatory Carcinoma of the Breast. <i>American Journal of Roentgenology</i> , 2000, 174, 535-538.	1.0	53

#	ARTICLE	IF	CITATIONS
73	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor ⁺ positive/human epidermal growth factor receptor 2 ⁻ negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	1.3	53
74	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , 2019, 65, 1405-1413.	1.5	53
75	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	7.7	52
76	A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer. <i>Cancer</i> , 2006, 107, 935-944.	2.0	51
77	Circulating Tumor Cells With Epithelial ⁻ to ⁺ mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 1829-1837.	0.5	49
78	Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. <i>Clinical Cancer Research</i> , 2002, 8, 615-9.	3.2	49
79	Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor ⁺ positive (HR+), human epidermal growth factor receptor 2 ⁻ negative (HER2 ⁻) advanced breast cancer (ABC): Updated analyses from PALOMA-3.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1000-1000.	0.8	47
80	Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics. <i>Communications Biology</i> , 2021, 4, 265.	2.0	46
81	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8 ⁺ /PDL1 ⁺ Immune Infiltration in Inflammatory Breast Cancer Tumors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1746-1756.	1.9	45
82	The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 6.	1.3	44
83	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	0.8	44
84	Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor- β Insensitive Genetically Targeted CD8 ⁺ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. <i>European Urology</i> , 2018, 73, 648-652.	0.9	43
85	Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 137.	2.2	42
86	Prospective changes in global DNA methylation and cancer incidence and mortality. <i>British Journal of Cancer</i> , 2016, 115, 465-472.	2.9	41
87	Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 219-230.	1.1	40
88	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020, 58, 102914.	2.7	40
89	Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer. <i>Journal of Proteome Research</i> , 2013, 12, 2805-2817.	1.8	38
90	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38

#	ARTICLE	IF	CITATIONS
91	EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. <i>Theranostics</i> , 2021, 11, 6632-6643.	4.6	38
92	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 2.	2.2	36
93	Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model. <i>Cell Cycle</i> , 2018, 17, 1536-1544.	1.3	35
94	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986606.	1.4	35
95	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. <i>European Journal of Cancer</i> , 2019, 106, 133-143.	1.3	35
96	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016, 29, 330-346.	2.9	33
97	A novel strategy to block mitotic progression for targeted therapy. <i>EBioMedicine</i> , 2019, 49, 40-54.	2.7	33
98	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2546-2555.	3.2	33
99	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	1.9	33
100	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021, 143, 147-157.	1.3	32
101	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12780-12785.	3.3	31
102	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017, 86, 257-265.	1.3	31
103	The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. <i>Journal of Experimental Therapeutics and Oncology</i> , 2013, 10, 219-33.	0.5	31
104	The biological information obtainable from circulating tumor cells. <i>Breast</i> , 2009, 18, S38-S40.	0.9	30
105	Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. <i>Clinical Cancer Research</i> , 2018, 24, 2732-2739.	3.2	30
106	Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 679-689.	1.1	30
107	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. <i>Cancer Research</i> , 2022, 82, 1321-1339.	0.4	30
108	Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. <i>BMC Cancer</i> , 2019, 19, 603.	1.1	29

#	ARTICLE	IF	CITATIONS
109	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
110	Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 526.	1.1	28
111	Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 733-741.	1.1	27
112	A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. <i>EBioMedicine</i> , 2019, 44, 98-111.	2.7	27
113	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020, 60, 344-350.	4.3	26
114	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	1.7	26
115	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1361-1370.	3.2	25
116	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <i>Oncotarget</i> , 2017, 8, 12417-12432.	0.8	24
117	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor ⁺ positive/human epidermal growth factor receptor 2 ⁻ negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. <i>Breast Cancer Research</i> , 2020, 22, 27.	2.2	24
118	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	2.1	23
119	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 943-952.	1.5	23
120	Circulating tumour cells in the -omics era: how far are we from achieving the "singularity"?. <i>British Journal of Cancer</i> , 2022, 127, 173-184.	2.9	23
121	The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. <i>Breast Cancer Research</i> , 2016, 18, 37.	2.2	21
122	Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 569-587.	1.1	21
123	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	1.1	21
124	Inflammatory breast cancer: a new approach. <i>Lancet Oncology</i> , The, 2016, 17, 544-546.	5.1	20
125	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	1.1	20
126	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	1.5	20

#	ARTICLE	IF	CITATIONS
127	Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2017, 35, e23028-e23028.	0.8	20
128	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health, 2018, 21, 1062-1068.	0.1	19
129	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer, 2019, 10, 3344-3351.	1.2	19
130	Antineoplastic effects of selective CDK9 inhibition with atuvaciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget, 2018, 9, 37305-37318.	0.8	19
131	Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. ELife, 2021, 10, .	2.8	18
132	Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics.. Journal of Clinical Oncology, 2017, 35, 3052-3052.	0.8	18
133	Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. Theranostics, 2022, 12, 2150-2161.	4.6	18
134	Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). Critical Reviews in Oncology/Hematology, 2020, 145, 102856.	2.0	17
135	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and <i>ESR1</i> mutations (mus) in circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2016, 34, 512-512.	0.8	17
136	Current state of clinical trials in breast cancer brain metastases. Neuro-Oncology Practice, 2019, 6, 392-401.	1.0	16
137	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist, 2021, 26, e1339-e1346.	1.9	16
138	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	1.2	15
139	Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. Current Problems in Diagnostic Radiology, 2019, 48, 235-240.	0.6	15
140	Hormone Receptorâ€“Positive/Human Epidermal Growth Receptor 2â€“Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. Oncologist, 2020, 25, e900-e908.	1.9	15
141	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. Oncologist, 2021, 26, e1143-e1155.	1.9	15
142	Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. Npj Breast Cancer, 2021, 7, 72.	2.3	15
143	Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy.. Journal of Clinical Oncology, 2017, 35, 1026-1026.	0.8	14
144	New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy. EMBO Molecular Medicine, 2020, 12, e12391.	3.3	14

#	ARTICLE	IF	CITATIONS
145	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Breast Cancer Research and Treatment</i> , 1999, 54, 225-233.	1.1	13
146	Novel targeted therapies in inflammatory breast cancer. <i>Cancer</i> , 2010, 116, 2837-2839.	2.0	13
147	A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process. <i>Translational Oncology</i> , 2015, 8, 358-367.	1.7	13
148	Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. , 2020, , .		13
149	Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1104-TPS1104.	0.8	13
150	NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. <i>Free Radical Biology and Medicine</i> , 2018, 126, 358-371.	1.3	12
151	Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. <i>Breast</i> , 2016, 29, 223-230.	0.9	11
152	Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1001-1001.	0.8	11
153	Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. <i>Oncotarget</i> , 2018, 9, 31606-31619.	0.8	11
154	Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1059.	0.8	11
155	Inflammatory Breast Cancer: Defining a New Entity. <i>Seminars in Oncology</i> , 2008, 35, 6.	0.8	10
156	New Treatment Strategies for the Inflammatory Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 50.	1.3	10
157	Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. <i>Cell Chemical Biology</i> , 2022, 29, 358-372.e5.	2.5	10
158	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 68.	1.3	9
159	Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11503-11503.	0.8	9
160	Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <i>ESR1</i> who have not experienced disease progression on first-line therapy. <i>Cancer Research</i> , 2022, 82, OT2-11-05-OT2-11-05.	0.4	9
161	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. <i>JCO Precision Oncology</i> , 2022, , .	1.5	9
162	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Breast Journal</i> , 2020, 26, 368-375.	0.4	8

#	ARTICLE	IF	CITATIONS
163	Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 397-405.	1.1	8
164	Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy “ results from Paloma-3.. <i>Journal of Clinical Oncology</i> , 2016, 34, 524-524.	0.8	8
165	Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1010-1010.	0.8	8
166	Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1009-1009.	0.8	8
167	Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. <i>Cancer</i> , 2019, 125, 2338-2344.	2.0	7
168	Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance. <i>Cellular Signalling</i> , 2020, 70, 109574.	1.7	7
169	Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1053-1053.	0.8	7
170	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 79.	1.7	7
171	Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy. <i>Molecular Cancer Research</i> , 2018, 16, 1844-1854.	1.5	6
172	Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1018-1018.	0.8	6
173	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. <i>Npj Breast Cancer</i> , 2022, 8, 12.	2.3	6
174	IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 56-59.	0.9	5
175	Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1009-1019.	2.3	5
176	A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1110-TPS1110.	0.8	5
177	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
178	A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1096-1096.	0.8	4
179	Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. <i>JCO Oncology Practice</i> , 2022, 18, 331-334.	1.4	4
180	Time for a shift in molecular down staging in luminal breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 2-3.	5.1	3

#	ARTICLE	IF	CITATIONS
181	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. Journal of Clinical Oncology, 2017, 35, 1514-1514.	0.8	3
182	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent-stage IV disease (Stage IV indolent).. Journal of Clinical Oncology, 2018, 36, 1019-1019.	0.8	3
183	Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC). Current Breast Cancer Reports, 2014, 6, 245-250.	0.5	2
184	Metastatic breast cancer: focus on endocrine sensitivity. Lancet, The, 2016, 388, 2961-2962.	6.3	2
185	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA Oncology, 2018, 4, 1430.	3.4	2
186	Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer. JAMA Oncology, 2020, 6, 1332.	3.4	2
187	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. Breast Cancer Research and Treatment, 2021, 190, 213-226.	1.1	2
188	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 11532-11532.	0.8	2
189	Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in PALOMA-3.. Journal of Clinical Oncology, 2017, 35, 1050-1050.	0.8	2
190	Concordance of mutations identified using circulating tumor DNA (ctDNA) compared to tissue based next generation sequencing (NGS) in gastrointestinal malignancies: A single institution experience.. Journal of Clinical Oncology, 2017, 35, e23023-e23023.	0.8	2
191	Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies.. Journal of Clinical Oncology, 2018, 36, 1090-1090.	0.8	2
192	Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3).. Journal of Clinical Oncology, 2019, 37, 1060-1060.	0.8	2
193	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1060-1060.	0.8	2
194	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-17-08-P5-17-08.	0.4	2
195	CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, 1093-1093.	0.8	2
196	Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?. Pharmacogenomics, 2015, 16, 669-672.	0.6	1
197	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. Journal of Clinical Oncology, 2021, 39, 1065-1065.	0.8	1
198	Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.. Journal of Clinical Oncology, 2021, 39, 5576-5576.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 8924.	1.8	1
200	Toxicity profile of approved anti-PD1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3064-3064.	0.8	1
201	Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1023-1023.	0.8	1
202	Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12097-12097.	0.8	1
203	Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?. <i>Journal of Clinical Oncology</i> , 2019, 37, 3038-3038.	0.8	1
204	ERBB2 amplifications and mutations in 109 advanced breast cancer patients by next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3565-3565.	0.8	1
205	Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS275-TPS275.	0.8	1
206	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). <i>Cancer Research</i> , 2022, 82, P2-07-02-P2-07-02.	0.4	1
207	Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P1-02-11-P1-02-11.	0.4	1
208	Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. <i>Cancers</i> , 2022, 14, 2872.	1.7	1
209	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 1-3.	0.9	0
210	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0
211	Understanding metastasis in breast cancer to improve detection, monitoring and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103462.	2.0	0
212	Classifying circulating, mutation bearing tumor cells from breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 580-580.	0.8	0
213	Circulating cancer associated macrophage-like cells in the detection of invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23055-e23055.	0.8	0
214	Concordance of genomic alterations by next generation sequencing (NGS) in tumor tissue vs. cell-free DNA in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11528-11528.	0.8	0
215	Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e23030-e23030.	0.8	0
216	Genomic aberrations in advanced solid malignancies using next generation sequencing: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23206-e23206.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Experience of implementing a novel random sampling BICR audit for investigator (INV)-assessed progression-free survival (PFS) in the PALOMA-3 trial.. Journal of Clinical Oncology, 2017, 35, 1058-1058.	0.8	0
218	Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers.. Journal of Clinical Oncology, 2018, 36, 12032-12032.	0.8	0
219	Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of "rapidly progressing" stage IV disease (Stage IVprog).. Journal of Clinical Oncology, 2018, 36, 12040-12040.	0.8	0
220	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 12039-12039.	0.8	0
221	Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).. Journal of Clinical Oncology, 2019, 37, 6557-6557.	0.8	0
222	Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).. Journal of Clinical Oncology, 2019, 37, 1036-1036.	0.8	0
223	Real-time monitoring of circulating stromal cells in the blood to predict responsiveness of new-line therapies in metastatic breast cancer.. Journal of Clinical Oncology, 2019, 37, e14048-e14048.	0.8	0
224	Keeping oncologists current with CDK4/6 inhibitors in HR+ breast cancer: The impact of online education.. Journal of Clinical Oncology, 2020, 38, e13044-e13044.	0.8	0
225	The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, 1084-1084.	0.8	0
226	Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.. Journal of Clinical Oncology, 2020, 38, 1028-1028.	0.8	0
227	IMPAssionate about immunotherapy for TNBC: from change, to revolution and to cure?. Annals of Translational Medicine, 2020, 8, 1537.	0.7	0
228	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. Cancer Research, 2022, 82, P2-02-05-P2-02-05.	0.4	0
229	Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using "real-world" data to describe this unique clinical entity. Cancer Research, 2022, 82, PD14-01-PD14-01.	0.4	0
230	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. Cancer Research, 2022, 82, P2-01-04-P2-01-04.	0.4	0
231	Abstract P2-01-08: "Esr1" Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. Cancer Research, 2022, 82, P2-01-08-P2-01-08.	0.4	0
232	Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy.. Journal of Clinical Oncology, 2022, 40, 3056-3056.	0.8	0
233	Abstract LB117: Pilot study to identify live circulating tumor cells (CTCs) in metastatic breast cancer (MBC) by application of a novel microfluidic workflow system and flow cytometry. Cancer Research, 2022, 82, LB117-LB117.	0.4	0
234	"ESR1" mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2022, 40, 1057-1057.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2022, 40, 3055-3055.	0.8	0